Thrivent Financial for Lutherans Has $771,000 Stock Position in Pediatrix Medical Group, Inc. (NYSE:MD)

Thrivent Financial for Lutherans cut its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 3.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,507 shares of the company’s stock after selling 2,364 shares during the period. Thrivent Financial for Lutherans owned about 0.08% of Pediatrix Medical Group worth $771,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Pediatrix Medical Group by 4.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 87,369 shares of the company’s stock valued at $877,000 after acquiring an additional 3,669 shares during the period. Tidal Investments LLC purchased a new stake in shares of Pediatrix Medical Group in the first quarter worth about $442,000. Virtu Financial LLC bought a new position in shares of Pediatrix Medical Group in the first quarter valued at approximately $124,000. Harbor Capital Advisors Inc. grew its stake in Pediatrix Medical Group by 48.0% during the second quarter. Harbor Capital Advisors Inc. now owns 54,480 shares of the company’s stock valued at $411,000 after acquiring an additional 17,678 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after acquiring an additional 1,524 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Insiders Place Their Bets

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Pediatrix Medical Group Price Performance

Shares of MD stock opened at $14.82 on Wednesday. The stock’s 50-day moving average price is $13.42 and its 200-day moving average price is $10.33. Pediatrix Medical Group, Inc. has a 12-month low of $6.62 and a 12-month high of $16.41. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same period last year, the company earned $0.29 EPS. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. Analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Truist Financial upped their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group increased their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. UBS Group upped their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, StockNews.com lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.